Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373229 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by David Rizzieri, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01373229: Completed Phase 1 study, sponsored by David Rizzieri, MD.
NCT01373229 is a Phase 1 study that has completed, run by David Rizzieri, MD. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01373229, a Phase 1 study, has completed, sponsored by David Rizzieri, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
In research studies, lenalidomide (also called Revlimid) has shown some response in chronic lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after several months of taking the study drug. It is thought that by adding the drug plerixafor (also called Mozobil) responses may be improved and/or occur sooner. The main purpose of this study is to determine the dose of plerixafor that is safe to use in combination with lenalidomide. The study will also look at the response rates of the combination of lenalidomide and plerixafor and the effect the study drugs have on CLL cells.
Interventions
- DRUG Lenalidomide + Plerixafor (+ Rituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT01373229 record still lists
NCT01373229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide + Plerixafor (+ Rituximab) is the first listed.
NCT01373229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01373229 about?
NCT01373229 is a clinical study titled "Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)". In research studies, lenalidomide (also called Revlimid) has shown some response in chronic lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after several months of taking the study drug. It is thought that by adding the drug plerixafor (also called Mozobil) re...
What is the current status of trial NCT01373229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01373229?
The interventions under investigation include: Lenalidomide + Plerixafor (+ Rituximab) (DRUG).
Who is sponsoring clinical trial NCT01373229?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01373229's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia